Mayne Pharma Group Limited operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Mayne Pharma Group Limited with three other
pharmaceutical manufacturers in Australasia:
AFT Pharmaceuticals Ltd
of New Zealand
sales of 69.21 million New Zealand Dollars [US$50.74 million]
of which 100%
(62.55 million Australian Dollars [US$49.29 million]
Vita Life Sciences Limited.
(37.74 million Australian Dollars [US$29.74 million]
During the year ended June of 2017, sales at
Mayne Pharma Group Limited were A$572.60 million (US$451.22 million).
increase of 114.2%
versus 2016, when the company's sales were A$267.28 million.
Sales of Generic Products saw an increase
that was more than double the company's growth rate: sales were up
291.9% in 2017, from
A$106.82 million to A$418.65 million.
Not all segments of Mayne Pharma Group Limited experienced an increase in sales in 2017:
sales of Specialty Brands fell 20.5% to A$61.86 million.